Alzamend Neuro Inc (NASDAQ: ALZN) on Friday, plunged -11.20% from the previous trading day, before settling in for the closing price of $1.25. Within the past 52 weeks, ALZN’s price has moved between $1.06 and $15.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 88.57%. With a float of $5.19 million, this company’s outstanding shares have now reached $5.23 million.
In an organization with 7 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 50.0%, operating margin of -7660.58%, and the pretax margin is -7686.14%.
Alzamend Neuro Inc (ALZN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Alzamend Neuro Inc is 4.56%, while institutional ownership is 0.77%. The most recent insider transaction that took place on Aug 06 ’24, was worth 206. In this transaction Director of this company bought 75 shares at a rate of $2.75, taking the stock ownership to the 77,268 shares. Before that another transaction happened on Jul 31 ’24, when Company’s Director bought 25 for $3.74, making the entire transaction worth $93. This insider now owns 77,193 shares in total.
Alzamend Neuro Inc (ALZN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 88.57% per share during the next fiscal year.
Alzamend Neuro Inc (NASDAQ: ALZN) Trading Performance Indicators
Alzamend Neuro Inc (ALZN) is currently performing well based on its current performance indicators. A quick ratio of 3.80 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.65, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.71 in one year’s time.
Technical Analysis of Alzamend Neuro Inc (ALZN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.3 million. That was inferior than the volume of 0.48 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.24%. Additionally, its Average True Range was 0.10.
During the past 100 days, Alzamend Neuro Inc’s (ALZN) raw stochastic average was set at 0.36%, which indicates a significant decrease from 17.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.24% in the past 14 days, which was lower than the 194.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4254, while its 200-day Moving Average is $4.1356. However, in the short run, Alzamend Neuro Inc’s stock first resistance to watch stands at $1.1833. Second resistance stands at $1.2567. The third major resistance level sits at $1.2933. If the price goes on to break the first support level at $1.0733, it is likely to go to the next support level at $1.0367. Assuming the price breaks the second support level, the third support level stands at $0.9633.
Alzamend Neuro Inc (NASDAQ: ALZN) Key Stats
Market capitalization of the company is 5.35 million based on 5,433K outstanding shares. Right now, sales total 0 K and income totals -9,950 K. The company made 0 K in profit during its latest quarter, and -1,360 K in sales during its previous quarter.
